ALK and non-small cell lung carcinoma: That analysis of published data collected over the last 20 years on the biochemistry and physiological effects of two drugs from general medical practice, itraconazole and cilostazol, intersect with ALK kinase (ALK) non-small cell lung cancers’ pathology to contribute to lorlatinib’s growth suppression of that cancer.